Skip to main content

Advertisement

SpringerLink
Log in

Addressing the Heterogeneity of Heart Failure in Future Randomized Trials

  • Management of Heart Failure (T Meyer, Section Editor)
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Purpose of the Review

The aim of review is to describe the essential role of study designs beyond RCTs in contemporary contest of HF patients giving perspectives on its evolving. The article concludes with concern about the support of observational studies for future randomized clinical trials.

Recent Findings

With the aging population and spectacular advance in cardiovascular therapy, the clinical syndrome comprising heart failure (HF) is increasingly in complexity of heterogeneity. It remains among the most challenging of clinical syndromes with a magnitude of proposed pathophysiological mechanisms involving the heart and the interplay with cardiac and non-cardiac comorbidities. In this epidemiological scenario, randomized clinical trials are suffering from growing failed treatment, so that a deeper understanding of heterogeneity represents a major unmet need. This field also is greatly in a more nuanced comprehension about the applicability in clinical practice of trials’ results derived from well-selected HF population. Thus, we need to reflect on trials failures and the translation of previous trials in clinical practice in order to redirect the future trial intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al. Executive summary: heart disease and stroke statistics—2012 update: a report from the American Heart Association. Circulation. 2012;125(1):188–97.

    Article  PubMed  Google Scholar 

  2. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30–41.

    Article  PubMed  Google Scholar 

  3. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–81.

    Article  CAS  PubMed  Google Scholar 

  4. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27(19):2338–45.

    Article  CAS  PubMed  Google Scholar 

  5. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67.

    Article  CAS  PubMed  Google Scholar 

  6. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, et al. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation. 2006;114(5):397–403.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA : the journal of the American Medical Association. 2013;310(23):2533–43.

    Article  CAS  PubMed  Google Scholar 

  8. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA : the journal of the American Medical Association. 2007;298(17):2009–19.

    Article  CAS  PubMed  Google Scholar 

  9. Konstam MA, Gheorghiade M, Burnett Jr JC, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA : the journal of the American Medical Association. 2007;297(12):1319–31.

    Article  CAS  PubMed  Google Scholar 

  10. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs. dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA : the journal of the American Medical Association. 2007;297(17):1883–91.

    Article  CAS  PubMed  Google Scholar 

  11. Packer M, Holcomb R, Abraham WT, Anker S, Dickstein K, Filippatos G, et al. Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. European journal of heart failure. 2016.

  12. • Senni M, Paulus WJ, Gavazzi A, Fraser AG, Diez J, Solomon SD, et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J. 2014;35(40):2797–815. This manuscript lead to better phenothyping of HF patients with preserved ejction fraction and offers an important issue for addressing future clinical randomized trials in this subset HF patients

    Article  PubMed  PubMed Central  Google Scholar 

  13. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, et al. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131(3):269–79.

    Article  PubMed  Google Scholar 

  14. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355(3):251–9.

    Article  CAS  PubMed  Google Scholar 

  15. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(1):65–75.

    Article  PubMed  Google Scholar 

  16. Iorio A SM, Poli S, Zambon E, Barbati G, Faganello G, Sinagra G, Tarantini L, Di Lenarda A, Cioffi G, Di Lenarda A. Impact of non-cardiac comorbidity on mortality and morbidity in a predominantly elderly heart failure population among different heart failure phenotypes. 2015;17((S1):141.

  17. Lam CS, Solomon SD. The middle child in heart failure: heart failure with mid-range ejection fraction (40–50%). Eur J Heart Fail. 2014;16(10):1049–55.

    Article  PubMed  Google Scholar 

  18. Komajda M, Lam CS. Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J. 2014;35(16):1022–32.

    Article  CAS  PubMed  Google Scholar 

  19. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.

    Article  PubMed  Google Scholar 

  20. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of cardiac failure. 20.;22(9):659–69.

  21. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381(9860):29–39.

    Article  CAS  PubMed  Google Scholar 

  22. Cannon JA, McKean AR, Jhund PS, McMurray JJ. What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold? Open heart. 2015;2(1):e000283.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364(9):797–805.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365(1):32–43.

    Article  PubMed  Google Scholar 

  25. Cleland JG, Chiswell K, Teerlink JR, Stevens S, Fiuzat M, Givertz MM, et al. Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study. Circulation Heart failure. 2014;7(1):76–87.

    Article  CAS  PubMed  Google Scholar 

  26. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–92.

    Article  CAS  PubMed  Google Scholar 

  27. • Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34–42. The authors demonstrated the regional differences of HF population enrollment in TOPCAT trial, yielding an important concern about the impact of regional varibility on trials’ results

    Article  CAS  PubMed  Google Scholar 

  28. Devereux RB, Roman MJ, Liu JE, Welty TK, Lee ET, Rodeheffer R, et al. Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study. Am J Cardiol. 2000;86(10):1090–6.

    Article  CAS  PubMed  Google Scholar 

  29. Sweitzer NK, Lopatin M, Yancy CW, Mills RM, Stevenson LW. Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (> or =55%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (<40%) fractions. Am J Cardiol. 2008;101(8):1151–6.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768–77.

    Article  PubMed  Google Scholar 

  31. Gustafsson F, Torp-Pedersen C, Brendorp B, Seibaek M, Burchardt H, Kober L. Long-term survival in patients hospitalized with congestive heart failure: relation to preserved and reduced left ventricular systolic function. Eur Heart J. 2003;24(9):863–70.

    Article  PubMed  Google Scholar 

  32. Cramer H, Lauche R, Haller H, Steckhan N, Michalsen A, Dobos G. Effects of yoga on cardiovascular disease risk factors: a systematic review and meta-analysis. Int J Cardiol. 2014;173(2):170–83.

    Article  PubMed  Google Scholar 

  33. Varela-Roman A, Grigorian L, Barge E, Bassante P, de la Pena MG, Gonzalez-Juanatey JR. Heart failure in patients with preserved and deteriorated left ventricular ejection fraction. Heart. 2005;91(4):489–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Crespo Leiro M, Drozdz J, et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808–17.

    Article  PubMed  Google Scholar 

  35. Senni M, Gavazzi A, Oliva F, Mortara A, Urso R, Pozzoli M, et al. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. Int J Cardiol. 2014;173(2):163–9.

    Article  PubMed  Google Scholar 

  36. Ezekowitz JA, Hu J, Delgado D, Hernandez AF, Kaul P, Leader R, et al. Acute heart failure: perspectives from a randomized trial and a simultaneous registry. Circulation Heart failure. 2012;5(6):735–41.

    Article  PubMed  Google Scholar 

  37. Ahmad T, Pencina MJ, Schulte PJ, O'Brien E, Whellan DJ, Pina IL, et al. Clinical implications of chronic heart failure phenotypes defined by cluster analysis. J Am Coll Cardiol. 2014;64(17):1765–74.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Braunwald E. Another step toward personalized care of patients with heart failure. Eur J Heart Fail. 2015;17(10):988–90.

    Article  PubMed  Google Scholar 

  39. D'Elia E, Vaduganathan M, Gori M, Gavazzi A, Butler J, Senni M. Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. Eur J Heart Fail. 2015;17(12):1231–9.

    Article  PubMed  Google Scholar 

  40. Senni M, Gavazzi A, Gheorghiade M, Butler J. Heart failure at the crossroads: moving beyond blaming stakeholders to targeting the heart. Eur J Heart Fail. 2015;17(8):760–3.

    Article  PubMed  Google Scholar 

  41. Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361–87.

    Article  PubMed  Google Scholar 

  42. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26(11):2389–430.

    Article  CAS  PubMed  Google Scholar 

  43. • Tavazzi L. Do we need clinical registries? Eur Heart J. 2014;35(1):7–9. The editorial focused on strikingly methodological issues of nationwide registries offering an important concerns on how conducting future observational research

    Article  PubMed  Google Scholar 

  44. Mejhert M, Persson H, Edner M, Kahan T. Epidemiology of heart failure in Sweden--a national survey. Eur J Heart Fail. 2001;3(1):97–103.

    Article  CAS  PubMed  Google Scholar 

  45. Lund LH, Oldgren J, James S. Registry-based pragmatic trials in heart failure: current experience and future directions. Current heart failure reports. 2017. Epub ahead of print.

  46. Ieva F, Gale CP, Sharples LD. Contemporary roles of registries in clinical cardiology: when do we need randomized trials? Expert Rev Cardiovasc Ther. 2014;12(12):1383–6.

    Article  CAS  PubMed  Google Scholar 

  47. Iorio ASM, Di Nora C, Barbati G, Cherubini A, Gavazzi A, Cioffi G, Pulignano G. Prognostic impact of polypharmacy drugs across heart failure phenotypes: an unmet need. Eur J Heart Fail. 2016;18(S1):109.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Papa Giovanni XXIII Hospital, Bergamo, Italy

    Annamaria Iorio, Andrea Pozzi & Michele Senni

Authors
  1. Annamaria Iorio
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Pozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michele Senni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michele Senni.

Ethics declarations

Conflict of Interest

Annamaria Iorio, Andrea Pozzi, and Michele Senni each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Topical Collection on Management of Heart Failure

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iorio, A., Pozzi, A. & Senni, M. Addressing the Heterogeneity of Heart Failure in Future Randomized Trials. Curr Heart Fail Rep 14, 197–202 (2017). https://doi.org/10.1007/s11897-017-0332-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-017-0332-1

Keywords

Search

Navigation